Sangamo BioSciences Expands Research Collaboration with Pfizer on Enhanced Protein Production

Sangamo BioSciences, Inc. has furthered its research collaboration with Pfizer Inc by entering into a second agreement that expands the scope of their existing research collaboration in the field of enhanced protein production. Through this agreement, Pfizer will fund further research at Sangamo, leveraging the company's zinc finger DNA-binding protein (ZFP) technology to develop additional cell lines for enhanced protein production. This partnership aligns with Sangamo's focus on developing novel DNA-binding proteins for therapeutic gene regulation and modification.

Key Takeaways:

The agreement between Sangamo BioSciences and Pfizer Inc expands the scope of their existing research collaboration in enhanced protein production.
Pfizer will fund further research at Sangamo to develop additional cell lines for enhanced protein production using Sangamo's zinc finger DNA-binding protein (ZFP) technology.
Zinc finger DNA-binding proteins (ZFPs) are the dominant class of naturally occurring transcription factors in organisms from yeast to humans.
Sangamo is developing ZFP transcription factors (ZFP TFs) that can control gene expression and consequently, cell function.
Sangamo is also developing sequence-specific ZFP nucleases (ZFNs) for targeted gene correction, gene disruption and gene insertion.
This partnership supports Sangamo's focus on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.
ZFPs are amenable to engineering and precise targeting to a specific gene or genes of interest.
The use of ZFPs enables the creation of cell lines with enhanced protein production capabilities.

Statistics:

Pfizer will fund further research at Sangamo.
Sangamo is developing additional cell lines for enhanced protein production using ZFP technology.
ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans.
Sangamo has developed ZFP TFs that can control gene expression and consequently, cell function.
Sangamo has developed ZFNs for targeted gene correction, gene disruption and gene insertion.
The agreement was announced in 2006.

Sources:

Health & Medicine Week editors
Staff and other reports